Achieve Life Sciences Bolsters Leadership Ahead of Cytisinicline Resubmission
Event summary
- Achieve Life Sciences appointed Ronald Dadino as SVP of CMC and Supply Chain, and Gloria Cosgrove as SVP of Quality on August 3, 2026.
- Both executives bring decades of experience in pharmaceutical manufacturing, supply chain, and quality from companies like Merck, Johnson & Johnson, Boehringer Ingelheim, and Regeneron.
- The appointments follow Craig Donnelly's departure as Chief Operations Officer, effective July 31, 2026.
- Achieve is preparing for the resubmission of its New Drug Application (NDA) and anticipated U.S. commercial launch of cytisinicline.
The big picture
Achieve Life Sciences is fortifying its leadership team ahead of a critical phase in its development. The appointments of Dadino and Cosgrove signal a focus on strengthening manufacturing, supply chain, and quality systems as the company prepares for commercialization. This move aligns with broader industry trends where late-stage biotech firms prioritize operational rigor to ensure regulatory approval and market readiness.
What we're watching
- Regulatory Readiness
- How the new leadership team will navigate the resubmission of the NDA and ensure compliance with FDA standards.
- Supply Chain Scaling
- Whether Achieve can successfully transition its finished product manufacturing to the United States and scale production reliably.
- Commercial Launch Pace
- The pace at which Achieve can bring cytisinicline to market, given the strategic hires and upcoming regulatory milestones.
Related topics